A clinical trial to evaluate the safety, efficacy, pharmacokinetics and biomarker data of evorpacept, dexamethasone and SARCLISA (isatuximab-irfc) for the treatment of patients with relapsed or refractory multiple myeloma ("RRMM")

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 02 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dexamethasone (Primary) ; Evorpacept (Primary) ; Isatuximab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Sanofi

Most Recent Events

02 May 2023 New trial record
25 Apr 2023 According to ALX Oncology Holdings Inc media release, the company has entered into a clinical trial collaboration and supply agreement with Sanofi; under the terms of agreement Sanofi will conduct this trial; ALX Oncology will supply evorpacept and Sanofi will supply SARCLISA for this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight